Table 5. Impact of treatment with inhibitors of gastric acid secretion on study outcomes.
Competing risks analysis.
| HR | 95% CI | p | Control variables* | |
|---|---|---|---|---|
| Enteric peritonitis | Diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR | |||
| IGAS overall | 1.51 | 1.00, 2.28 | 0.052 | |
| PPI | 1.11 | 0.79, 2.65 | 0,62 | |
| H2A | 1.40 | 0.90, 2.18 | 0.14 | |
| Infectious mortality | Age, diabetes, Charlson, albumin, immunosuppression, hemoglobin, GFR | |||
| IGAS overall | 1.35 | 0.98, 1.88 | 0.081 | |
| PPI | 0.58 | 0.32, 1.02 | 0.066 | |
| H2A | 2.25 | 1.36, 3.70 | 0.0015 | |
| Overall peritonitis | Age. albumin, immunosuppression, GFR, hemoglobin, Modality of PD | |||
| IGAS overall | 1.20 | 0.97, 1.51 | 0.09 | |
| PPI | 1.20 | 0.95, 1.52 | 0.12 | |
| H2A | 1.04 | 0.80, 1.35 | 0.76 |
IGAS: Inhibitors of gastric acid secretion; PPI: Proton pump inhibitors; H2A: H2 receptor antagonists.
* Independent predictors of outcome in best model. PD vintage NS
Competing events: Overall mortality (overall and enteric peritonitis) and non-infectious mortality (Infectious mortality)